Fluocinonide

Generic Name: Fluocinonide

Brand Names: Lidemol, Lidex, Lyderm, Tiamol, Vanos

Drug Type: Small Molecule

Chemical Formula: C_₂₆H_₃₂F_₂O_₇

CAS Number: 356-12-7

Unique Ingredient Identifier: 2W4A77YPAN

Overview

A topical glucocorticoid used in the treatment of eczema.

Indication

A topical anti-inflammatory product for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Associated Conditions

Dermatosis
Inflammation
Pruritus

Clinical Trials

Title	Posted	Study ID	Phase	Status	Sponsor
Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)	2024/07/16	NCT06504160	Phase 1	Recruiting	National Institute of Allergy and Infectious Diseases (NIAID)
Impact of Fluocinonide 0,05% in Oral Lichen Planus	2023/11/18	NCT06135805	Not Applicable	Recruiting	University of Catania
Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma	2014/11/26	NCT02301494	Not Applicable	Withdrawn	Rochester General Hospital
Cutaneous Lupus Medication Experience Study	2014/06/26	NCT02176148	N/A	Completed	Wake Forest University Health Sciences
Using an Internet Study to Improve Adherence for Psoriasis Patients	2013/03/01	NCT01802580	Early Phase 1	Completed	Wake Forest University
Efficacy of Fluocinonide Cream 0.1% (Vanos(R)) in Reducing Itch in Subjects With Atopic Dermatitis	2011/11/10	NCT01469767	Phase 2	Completed	Wake Forest University
Fluocinonide Cream in Treating Symptoms of Vaginal Dryness and Painful Sexual Intercourse In Patients With Breast Cancer Undergoing Hormone Therapy	2011/08/24	NCT01422408	Phase 2	Completed	OHSU Knight Cancer Institute
A Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis	2010/01/14	NCT01049243	Phase 4	Completed	Wake Forest University Health Sciences
VANOS Cream and Skin Barrier Function	2009/01/09	NCT00819507	Phase 4	Completed	Oregon Health and Science University
Sorafenib-induced Hand- Foot Skin Reaction Treatment	2008/04/28	NCT00667589	Phase 2	Terminated	Northwestern University

FDA Drug Approvals

Approved Product	Manufacturer	NDC Code	Route	Strength	Effective Date
Fluocinonide	Teligent Pharma, Inc.	52565-040	TOPICAL	0.5 mg in 1 g	8/12/2016
Fluocinonide	IPG PHARMACEUTICALS, INC.	71085-005	TOPICAL	0.5 mg in 1 g	2/15/2017
Fluocinonide	A-S Medication Solutions	50090-2419	TOPICAL	0.5 mg in 1 g	12/6/2022
Fluocinonide	Aidarex Pharmaceuticals LLC	33261-560	TOPICAL	0.5 mg in 1 g	8/23/2018
Fluocinonide	Asclemed USA, Inc.	76420-509	TOPICAL	1 mg in 1 g	12/16/2023
Fluocinonide	NuCare Pharmaceuticals,Inc.	68071-1754	TOPICAL	0.5 mg in 1 g	2/11/2021
Fluocinonide	NuCare Pharmaceuticals, Inc.	66267-973	TOPICAL	0.5 mg in 1 g	1/11/2021
Fluocinonide	NuCare Pharmaceuticals,Inc.	68071-4921	TOPICAL	0.5 mg in 1 g	2/18/2021
Fluocinonide Cream	Preferred Pharmaceuticals Inc.	68788-8105	TOPICAL	0.5 mg in 1 g	6/8/2023
Fluocinonide Cream	NuCare Pharmaceuticals,Inc.	68071-2808	TOPICAL	0.5 mg in 1 g	8/8/2022

EMA Drug Approvals

Approved Product	Authorization Holder	Status	Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product	Manufacturer	Approval Number	Dosage Form	Strength	Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product	Company	Approval Number	Drug Type	Dosage Form	Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product	Registration No.	Company	Licence No.	Strength	Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product	ARTG ID	Sponsor	Registration Type	Status	Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product	Company	DIN	Dosage Form	Strength	Market Date
LIDEMOL 0.05%	syntex inc.	00424943	Cream , Emulsion - Topical	.05 %	12/31/1979
LYDERM	taropharma, a division of taro pharmaceuticals inc.	00716863	Cream - Topical	0.05 % / W/W	12/31/1988
LYDONIDE EMOLLIENT CREAM 0.05%	technilab pharma inc.	02187671	Cream - Topical	.05 %	7/30/1996
LIDEMOL	bausch health, canada inc.	02163152	Cream - Topical	0.05 % / W/W	12/31/1995
LIDEX OINTMENT MILD 0.01%	medicis canada ltd.	00274445	Ointment - Topical	0.01 %	12/31/1973
TOPSYN 0.05%	syntex inc.	00281913	Jelly - Topical	.5 MG / G	12/31/1973
LIDEX CREAM MILD 0.01%	medicis canada ltd.	00274453	Cream - Topical	0.01 %	12/31/1972
LIDEX ONT 0.05%	syntex inc.	00274437	Ointment - Topical	.05 %	12/31/1973
LIDEX	bausch health, canada inc.	02161923	Cream - Topical	0.05 % / W/W	12/31/1996
LYDERM	taropharma, a division of taro pharmaceuticals inc.	02236996	Ointment - Topical	0.05 %	10/15/1999

CIMA AEMPS Drug Approvals

Approved Product	Company	Registration Number	Pharmaceutical Form	Prescription Type	Status
NOVOTER 0,5 MG/G CREMA	Teofarma S.R.L.	54036	CREMA	Medicamento Sujeto A Prescripción Médica	Commercialized
ABRASONE RECTAL, CREMA RECTAL	Anotaciones Farmaceuticas, S.L.	56385	CREMA RECTAL	Sin Receta	Commercialized
NOVOTER GENTAMICINA 0,5 MG/G + 1 MG/G CREMA	Teofarma S.R.L.	54003	CREMA	Medicamento Sujeto A Prescripción Médica	Commercialized

Philippines FDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product	Company	License Number	Dosage Form	Strength	Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product	Company	Registration Number	Dosage Form	Strength	Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name	MA Holder	MA Number	Pharmaceutical Form	Active Ingredient	Authorization Date
No UK EMC drug information found for this drug.

Related News

No news found

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Product

Company

Legal

© 2025 MedPath, Inc. All rights reserved.